Genetic correction of PSA values using sequence variants associated with PSA levels

Science Translational Medicine

Volumn 2, Issue 62, 2010, Pages

  Gudmundsson, Julius ^a   Besenbacher, Soren ^a   Sulem, Patrick ^a   Gudbjartsson, Daniel F ^a   Olafsson, Isleifur ^b   Arinbjarnarson, Sturla ^c   Agnarsson, Bjarni A ^b,d   Benediktsdottir, Kristrun R ^b,d   Isaksson, Helgi J ^b   Kostic, Jelena P ^a   Gudjonsson, Sigurjon A ^a   Stacey, Simon N ^a   Gylfason, Arnaldur ^a   Sigurdsson, Asgeir ^a   Holm, Hilma ^a   Bjornsdottir, Unnur S ^d   Eyjolfsson, Gudmundur I ^e   Navarrete, Sebastian ^f   Fuertes, Fernando ^f   Garcia Prats, Maria D ^g   Polo, Eduardo ^h   Checherita, Ionel A ⁱ   Jinga, Mariana ⁱ   Badea, Paula ^j   Aben, Katja K ^k,l   Schalken, Jack A ^l   Van Oort, Inge M ^l   Sweep, Fred C ^l   Helfand, Brian T ^m   Davis, Michael ⁿ   Donovan, Jenny L ⁿ   Hamdy, Freddie C ^o   Kristjansson, Kristleifur ^a   Gulcher, Jeffrey R ^a   Masson, Gisli ^a   Kong, Augustine ^a   Catalona, William J ^m   Mayordomo, Jose I ^p   Geirsson, Gudmundur ^b   Einarsson, Gudmundur V ^b   Barkardottir, Rosa B ^b,d   Jonsson, Eirikur ^b   Jinga, Viorel ⁱ   Mates, Dana ^j   Kiemeney, Lambertus A ^k,l   Neal, David E ^q   Thorsteinsdottir, Unnur ^a,d   Rafnar, Thorunn ^a   Stefansson, Kari ^a,d   more..

^a DECODE GENETICS   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c Glaesibaer   (Iceland)

^d UNIVERSITY OF ICELAND   (Iceland)

^e Laboratory in Mjodd   (Iceland)

^f HOSPITAL SAN JORGE   (Spain)

^g San Jorge General Hospital   (Spain)

^h Royo Villanova Hospital   (Spain)

ⁱ CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^k Integraal Kankercentrum Oost   (Netherlands)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF BRISTOL   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^q UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; KALLIKREIN; KALLIKREIN 3; PROSTATE SPECIFIC ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX3; UNCLASSIFIED DRUG; BETA-MICROSEMINOPROTEIN; FGFR2 PROTEIN, HUMAN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATIC SECRETORY PROTEIN; T BOX TRANSCRIPTION FACTOR; TBX3 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 12; CHROMOSOME 12Q; CHROMOSOME 17; CHROMOSOME 17Q; CHROMOSOME 19; CHROMOSOME 19Q; CHROMOSOME 5; CONTROLLED STUDY; FOLLOW UP; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; ICELAND; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; ROMANIA; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; UNITED STATES; BLOOD; EARLY DIAGNOSIS; GENETIC MARKER; GENETICS; METHODOLOGY; PROSTATE TUMOR;

EARLY DETECTION OF CANCER; GENETIC MARKERS; HUMANS; KALLIKREINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; T-BOX DOMAIN PROTEINS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650468754     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001513     Document Type: Article

References (26)

1. M. J. Barry, Screening for prostate cancer - the controversy that refuses to die. N. Engl. J. Med. 360, 1351-1354 (2009).
2. G. Aus, J. E. Damber, A. Khatami, H. Lilja, J. Stranne, J. Hugosson, Individualized screening interval for prostate cancer based on prostate-specific antigen level: Results of a prospective, randomized, population-based study. Arch. Intern. Med. 165, 1857-1861 (2005).
3. R. K. Nam, W. W. Zhang, J. Trachtenberg, A. Seth, L. H. Klotz, A. Stanimirovic, S. Punnen, V. Venkateswaran, A. Toi, D. A. Loblaw, L. Sugar, K. A. Siminovitch, S. A. Narod, Utility of incorporating genetic variants for the early detection of prostate cancer. Clin. Cancer Res. 15, 1787-1793 (2009).
4. I. M. Thompson, D. P. Ankerst, C. Chi, P. J. Goodman, C. M. Tangen, M. S. Lucia, Z. Feng, H. L. Parnes, C. A. Coltman Jr., Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 98, 529-534 (2006).
5. F. H. Schröder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Määttänen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning, A. Auvinen; ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
6. G. L. Andriole, E. D. Crawford, R. L. Grubb III, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg; PLCO Project Team, Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
7. P. J. van Leeuwen, D. Connolly, A. Gavin, M. J. Roobol, A. Black, C. H. Bangma, F. H. Schröder, Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. Eur. J. Cancer 46, 377-383 (2010).
8. J. Hugosson, S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, P. Lodding, C. G. Pihl, J. Stranne, E. Holmberg, H. Lilja, Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11, 725-732 (2010).
9. E. D. Crawford, R. Grubb III, A. Black, G. L. Andriole Jr., M. H. Chen, G. Izmirlian, C. D. Berg, A. V. D'Amico, Comorbidity and mortality results from a randomized prostate cancer screening trial. J. Clin. Oncol. 10.1200/JCO.2010.30.5979 (2010).
10. V. Emilsson, G. Thorleifsson, B. Zhang, A. S. Leonardson, F. Zink, J. Zhu, S. Carlson, A. Helgason, G. B. Walters, S. Gunnarsdottir, M. Mouy, V. Steinthorsdottir, G. H. Eiriksdottir, G. Bjornsdottir, I. Reynisdottir, D. Gudbjartsson, A. Helgadottir, A. Jonasdottir, A. Jonasdottir, U. Styrkarsdottir, S. Gretarsdottir, K. P. Magnusson, H. Stefansson, R. Fossdal, K. Kristjansson, H. G. Gislason, T. Stefansson, B. G. Leifsson, U. Thorsteinsdottir, J. R. Lamb, J. R. Gulcher, M. L. Reitman, A. Kong, E. E. Schadt, K. Stefansson, Genetics of gene expression and its effect on disease. Nature 452, 423-428 (2008).
11. A. Bansal, D. K. Murray, J. T. Wu, R. A. Stephenson, R. G. Middleton, A. W. Meikle, Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. J. Clin. Endocrinol. Metab. 85, 1272-1276 (2000).
12. G. Pilia, W. M. Chen, A. Scuteri, M. Orrú, G. Albai, M. Dei, S. Lai, G. Usala, M. Lai, P. Loi, C. Mameli, L. Vacca, M. Deiana, N. Olla, M. Masala, A. Cao, S. S. Najjar, A. Terracciano, T. Nedorezov, A. Sharov, A. B. Zonderman, G. R. Abecasis, P. Costa, E. Lakatta, D. Schlessinger, Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet. 2, e132 (2006).
13. R. A. Eeles, Z. Kote-Jarai, G. G. Giles, A. A. Olama, M. Guy, S. K. Jugurnauth, S. Mulholland, D. A. Leongamornlert, S. M. Edwards, J. Morrison, H. I. Field, M. C. Southey, G. Severi, J. L. Donovan, F. C. Hamdy, D. P. Dearnaley, K. R. Muir, C. Smith, M. Bagnato, A. T. Ardern-Jones, A. L. Hall, L. T. O'Brien, B. N. Gehr-Swain, R. A. Wilkinson, A. Cox, S. Lewis, P. M. Brown, S. G. Jhavar, M. Tymrakiewicz, A. Lophatananon, S. L. Bryant, UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; A. Horwich, R. A. Huddart, V. S. Khoo, C. C. Parker, C. J. Woodhouse, A. Thompson, T. Christmas, C. Ogden, C. Fisher, C. Jamieson, C. S. Cooper, D. R. English, J. L. Hopper, D. E. Neal, D. F. Easton, Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316-321 (2008).
14. J. Ahn, S. I. Berndt, S. Wacholder, P. Kraft, A. S. Kibel, M. Yeager, D. Albanes, E. Giovannucci, M. J. Stampfer, J. Virtamo, M. J. Thun, H. S. Feigelson, G. Cancel-Tassin, O. Cussenot, G. Thomas, D. J. Hunter, J. F. Fraumeni Jr., R. N. Hoover, S. J. Chanock, R. B. Hayes, Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat. Genet. 40, 1032-1034 (2008).
15. F. Wiklund, S. L. Zheng, J. Sun, H. O. Adami, H. Lilja, F. C. Hsu, P. Stattin, J. Adolfsson, S. D. Cramer, D. Duggan, J. D. Carpten, B. L. Chang, W. B. Isaacs, H. Grönberg, J. Xu, Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 69, 419-427 (2009).
16. D. F. Gudbjartsson, G. B. Walters, G. Thorleifsson, H. Stefansson, B. V. Halldorsson, P. Zusmanovich, P. Sulem, S. Thorlacius, A. Gylfason, S. Steinberg, A. Helgadottir, A. Ingason, V. Steinthorsdottir, E. J. Olafsdottir, G. H. Olafsdottir, T. Jonsson, K. Borch-Johnsen, T. Hansen, G. Andersen, T. Jorgensen, O. Pedersen, K. K. Aben, J. A. Witjes, D. W. Swinkels, M. den Heijer, B. Franke, A. L. Verbeek, D. M. Becker, L. R. Yanek, L. C. Becker, L. Tryggvadottir, T. Rafnar, J. Gulcher, L. A. Kiemeney, A. Kong, U. Thorsteinsdottir, K. Stefansson, Many sequence variants affecting diversity of adult human height. Nat. Genet. 40, 609-615 (2008).
17. G. Thomas, K. B. Jacobs, M. Yeager, P. Kraft, S. Wacholder, N. Orr, K. Yu, N. Chatterjee, R. Welch, A. Hutchinson, A. Crenshaw, G. Cancel-Tassin, B. J. Staats, Z. Wang, J. Gonzalez-Bosquet, J. Fang, X. Deng, S. I. Berndt, E. E. Calle, H. S. Feigelson, M. J. Thun, C. Rodriguez, D. Albanes, J. Virtamo, S. Weinstein, F. R. Schumacher, E. Giovannucci, W. C. Willett, O. Cussenot, A. Valeri, G. L. Andriole, E. D. Crawford, M. Tucker, D. S. Gerhard, J. F. Fraumeni Jr., R. Hoover, R. B. Hayes, D. J. Hunter, S. J. Chanock, Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310-315 (2008).
18. K. M. Waters, D. O. Stram, L. Le Marchand, R. J. Klein, C. Valtonen-André, M. T. Peltola, L. N. Kolonel, B. E. Henderson, H. Lilja, C. A. Haiman, A common prostate cancer risk variant 5′ of microseminoprotein-β (MSMB) is a strong predictor of circulating β-microseminoprotein (MSP) levels in multiple populations. Cancer Epidemiol. Biomarkers Prev. 19, 2639-2646 (2010).
19. X. Xu, C. Valtonen-André, C. Sävblom, C. Halldén, H. Lilja, R. J. Klein, Polymorphisms at the microseminoprotein-β locus associated with physiologic variation in β-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol. Biomarkers Prev. 19, 2035-2042 (2010).
20. R. J. Klein, C. Halldén, A. M. Cronin, A. Ploner, F. Wiklund, A. S. Bjartell, P. Stattin, J. Xu, P. T. Scardino, K. Offit, A. J. Vickers, H. Grönberg, H. Lilja, Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: Kallikreins and prostate cancer. Cancer Prev. Res. 3, 611-619 (2010).
21. P. Pal, H. Xi, G. Sun, R. Kaushal, J. J. Meeks, C. S. Thaxton, S. Guha, C. H. Jin, B. K. Suarez, W. J. Catalona, R. Deka, Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum. Genet. 122, 251-259 (2007).
22. J. Gudmundsson, P. Sulem, V. Steinthorsdottir, J. T. Bergthorsson, G. Thorleifsson, A. Manolescu, T. Rafnar, D. Gudbjartsson, B. A. Agnarsson, A. Baker, A. Sigurdsson, K. R. Benediktsdottir, M. Jakobsdottir, T. Blondal, S. N. Stacey, A. Helgason, S. Gunnarsdottir, A. Olafsdottir, K. T. Kristinsson, B. Birgisdottir, S. Ghosh, S. Thorlacius, D. Magnusdottir, G. Stefansdottir, K. Kristjansson, Y. Bagger, R. L. Wilensky, M. P. Reilly, A. D. Morris, C. H. Kimber, A. Adeyemo, Y. Chen, J. Zhou, W. Y. So, P. C. Tong, M. C. Ng, T. Hansen, G. Andersen, K. Borch-Johnsen, T. Jorgensen, A. Tres, F. Fuertes, M. Ruiz-Echarri, L. Asin, B. Saez, E. van Boven, S. Klaver, D. W. Swinkels, K. K. Aben, T. Graif, J. Cashy, B. K. Suarez, O. van Vierssen Trip, M. L. Frigge, C. Ober, M. H. Hofker, C. Wijmenga, C. Christiansen, D. J. Rader, C. N. Palmer, C. Rotimi, J. C. Chan, O. Pedersen, G. Sigurdsson, R. Benediktsson, E. Jonsson, G. V. Einarsson, J. I. Mayordomo, W. J. Catalona, L. A. Kiemeney, R. B. Barkardottir, J. R. Gulcher, U. Thorsteinsdottir, A. Kong, K. Stefansson, Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39, 977-983 (2007).
23. The NIH Catalog of Published Genome-Wide Association Studies, http://www.genome.gov/26525384#1.
24. T. Rafnar, P. Sulem, S. N. Stacey, F. Geller, J. Gudmundsson, A. Sigurdsson, M. Jakobsdottir, H. Helgadottir, S. Thorlacius, K. K. Aben, T. Blöndal, T. E. Thorgeirsson, G. Thorleifsson, K. Kristjansson, K. Thorisdottir, R. Ragnarsson, B. Sigurgeirsson, H. Skuladottir, T. Gudbjartsson, H. J. Isaksson, G. V. Einarsson, K. R. Benediktsdottir, B. A. Agnarsson, K. Olafsson, A. Salvarsdottir, H. Bjarnason, M. Asgeirsdottir, K. T. Kristinsson, S. Matthiasdottir, S. G. Sveinsdottir, S. Polidoro, V. Höiom, R. Botella-Estrada, K. Hemminki, P. Rudnai, D. T. Bishop, M. Campagna, E. Kellen, M. P. Zeegers, P. de Verdier, A. Ferrer, D. Isla, M. J. Vidal, R. Andres, B. Saez, P. Juberias, J. Banzo, S. Navarrete, A. Tres, D. Kan, A. Lindblom, E. Gurzau, K. Koppova, F. de Vegt, J. A. Schalken, H. F. van der Heijden, H. J. Smit, R. A. Termeer, E. Oosterwijk, O. van Hooij, E. Nagore, S. Porru, G. Steineck, J. Hansson, F. Buntinx, W. J. Catalona, G. Matullo, P. Vineis, A. E. Kiltie, J. I. Mayordomo, R. Kumar, L. A. Kiemeney, M. L. Frigge, T. Jonsson, H. Saemundsson, R. B. Barkardottir, E. Jonsson, S. Jonsson, J. H. Olafsson, J. R. Gulcher, G. Masson, D. F. Gudbjartsson, A. Kong, U. Thorsteinsdottir, K. Stefansson, Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227 (2009).
25. J. Xu, S. D. Isaacs, J. Sun, G. Li, K. E. Wiley, Y. Zhu, F. C. Hsu, F. Wiklund, A. R. Turner, T. S. Adams, W. Liu, B. J. Trock, A. W. Partin, B. Chang, P. C. Walsh, H. Grönberg, W. Isaacs, S. Zheng, Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin. Cancer Res. 14, 5819-5824 (2008).
26. A. K. Kader, J. Sun, S. D. Isaacs, K. E. Wiley, G. Yan, S. T. Kim, H. Fedor, A. M. DeMarzo, J. I. Epstein, P. C. Walsh, A. W. Partin, B. Trock, S. L. Zheng, J. Xu, W. Isaacs, Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 69, 1195-1205 (2009).